Reporting owner · CIK 0002037144

Coll Crespo Blas

SEC Form 4 history for the last 180 days across 1 company, 4 transactions and 1 filing.

CMOCHIEF MEDICAL OFFICERStructure Therapeutics Inc.
Open-market transaction mix0% buys0 buys · 1 sale

Period: Last 180 days

Trade dates in this period: Sep 18, 2026 – Sep 21, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$145k1 sale
Net value−$145kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Coll Crespo Blas transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
GPCRStructure Therapeutics Inc.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
−$145kView disclosure →
GPCRStructure Therapeutics Inc.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Conversion
Form 4 code C. Conversion of a derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
GPCRStructure Therapeutics Inc.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Conversion
Form 4 code C. Conversion of a derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$0View disclosure →
GPCRStructure Therapeutics Inc.
CMO
CMO. Role codes can represent multiple titles; the list does not include the filing title.
Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$124kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at Structure Therapeutics Inc. on Sep 21, 2026 valued at $144,872.77.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Sep 202601$0$144,872.77−$144,872.77

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$145k
Median P/S size$145k
Direct4
Indirect0
Sep 21, 2026sale

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Sep 18, 2026 – Sep 21, 2026. Window ends at the latest available report, not today.

Selected observation · Sep 21, 2026258,228 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Sep 18, 2026270,252Sep 22, 2026View transaction
Sep 21, 2026258,228Sep 22, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Coll Crespo Blas Insider Activity FAQ

SEC Form 4 context

Who is Coll Crespo Blas?

Coll Crespo Blas is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002037144.

Which companies has Coll Crespo Blas reported transactions for?

Structure Therapeutics Inc.

When was Coll Crespo Blas's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Coll Crespo Blas's latest insider sale?

The insider reported a sale at Structure Therapeutics Inc. on Sep 21, 2026 valued at $144,872.77.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.